Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $122

Benzinga Newsdesk www.benzinga.com Positive 93.4%

Neg 0% Neu 0% Pos 93.4%

Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target from $114 to $122.